Bristol Myers Squibb appoints Cristian Massacesi as chief medical officer and head of development
July 28, 2025Research and Development Bristol Myer Squibb, Corporate, Executive Leadership Team, Head of Development, chief medical officer, executive vice president
Bristol Myers Squibb (BMS) has announced the appointment of Cristian Massacesi as executive vice president, chief medical officer, and head …
Neuraxpharm appoints Avendran Naidu as head of commercial upon launch of Australian affiliate
July 28, 2025Manufacturing and Production, Research and Development Neuraxpharm, Neuraxpharm Australia, Neurology, central nervous system, multiple sclerosis
Neuraxpharm Group has announced the launch of Neuraxpharm Australia, furthering its global expansion beyond Europe and into key international markets. …
Seaport Therapeutics doses first patient in trial of GlyphAllo for depression
July 25, 2025Research and Development Psychiatry, Seaport Therapeutics, clinical trial, major depressive disorder, mental health, neuropsychiatric conditions
Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo (SPT-300), an oral prodrug of …
Cube Biotech appoints Michael Bencak as new CEO amid global expansion plans
July 25, 2025Mergers and Acquisitions, Research and Development CEO, Corporate, Cube Biotech, IBA Lifescience, archimed, executive chairman
Cube Biotech has announced a leadership transition as the company continues its trajectory of global growth and innovation in protein …
PureTech Health appoints interim CEO Robert Lyne
July 24, 2025Research and Development Corporate, PureTech Health, board of directors, chief portfolio officer, interim CEO
PureTech Health has announced the departure of chief executive officer (CEO) Bharatt Chowrira, who has stepped down from his role …
OKYO Pharma reports promising phase 2 results for urcosimod in neuropathic corneal pain
July 24, 2025Research and Development OKYO Pharma, Opthalmology, clinical trial, neuropathic corneal pain, ocular pain
OKYO Pharma has announced positive results from its phase 2 trial of urcosimod (formerly OK-101) in neuropathic corneal pain (NCP), …
Yourgene Health launches LightBench Discover for long-read sequencing labs
July 23, 2025Business Services, Technical Consultancy Devices, Novacyt, PacBio, Yourgene Health, molecular diagnostics
Yourgene Health, part of the Novacyt group, has announced the launch of LightBench Discover, an integrated benchtop instrument designed to …
Evestia Clinical and Atlantic Research Group merge to create global specialist CRO
July 23, 2025Clinical Trial Services, Mergers and Acquisitions, Research and Development Atlantic Research Group, Corporate, Evestia Clinical, clinical trials, contract research organisation
UK-based Evestia Clinical will merge with US-based Atlantic Research Group (ARG), forming a leading independent global contract research organisation (CRO) …
MetP Pharma releases positive data on intranasal semaglutide administration
July 22, 2025Research and Development Diabetes, MetP Pharma, Neurology, Obesity, central nervous system, diabetes, obesity, peptides, semaglutide
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering neuroactive peptides, particularly semaglutide, directly …
Takara and Macherey-Nagel enter distribution agreement for global expansion
July 22, 2025Mergers and Acquisitions Devices, Macherey-Nagel, Microbiology, Takara, Takara Bio Europe
Takara Bio Europe has entered into a distribution agreement with Macherey-Nagel (MN), an analytical and bioanalytical product provider, to expand …
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
July 21, 2025Medical Communications, Mergers and Acquisitions, Research and Development Boehringer Ingelheim, Dermatology, LEO Pharma, Spevigo, generalised pustular psoriasis, partnership, skin disease
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a treatment for generalised pustular psoriasis …
LDC strengthens healthcare focus with appointment of Amit Thaper as investment director
July 21, 2025Business Services, Industry Associations, Research and Development Corporate, Inicio Health, Investment Director, LDC, RDi
LDC, the private equity arm of Lloyds Banking Group, has strengthened its healthcare expertise with the appointment of Amit Thaper …
Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse
July 18, 2025Medical Communications, Research and Development CAPLYTA, Johnson & Johnson, Neurology, US Food and Drug Administration, neuroscience, new drug application, schizophrenia
Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Caplyta …
EMA lifts temporary ban on chikungunya vaccine Ixchiq following safety review
July 18, 2025Medical Communications Committee for Medicinal Products for Human USE, European Medicines Agency (EMA), Ixchiq, Pharmacovigilance Risk Assessment Committee (PRAC), Vaccine, Virology, chikungunya
After completing a safety review of Ixchiq – a vaccine for chikungunya – the European Medicines Agency’s (EMA) safety committee …
Addenbrooke’s hospital offers first self-service digital eye test
July 17, 2025Research and Development Addenbrooke's Hospital, Cambridge, Opthalmology, UK, eye test, ophthalmology
Addenbrooke’s Hospital, Cambridge, has become the first in the UK to deploy a digital self-testing system – DigiVis DVA system …
Biogen and Stoke report positive results for Dravet syndrome drug
July 17, 2025Research and Development Biogen, Dravet Syndrome, Neurology, Stoke Therapeutics, epilepsy, rare diseases
Biogen and Stoke Therapeutics have shared encouraging new data for their experimental treatment, zorevunersen, which is being developed for Dravet …
FDA approves Moderna’s Spikevax for children at increased risk of COVID-19
July 16, 2025Medical Communications COVID-19, Spikevax, US Food and Drug Administration, Vaccine, Virology
Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, Spikevax, in children aged six …
Jazz Pharmaceuticals appoints Renée Galá as CEO to lead next phase of growth
July 16, 2025Research and Development CEO, Corporate, Neurology, Oncology, jazz pharmaceuticals, neurology, neuroscience
Jazz Pharmaceuticals has named Renée Galá as its next chief executive officer (CEO), effective 11 August 2025. Galá, currently president …
Osivax publishes positive results from trial of influenza vaccine candidate
July 15, 2025Research and Development Osivax, Vaccine, Virology, clinical trial, influenza, respiratory diseases
French biopharma, Osivax, has announced positive results from its phase 2 study, OVX836-004, into OVX836, its broad-spectrum influenza vaccine lead …
Pharvaris to report phase 3 data and submit New Drug Application
July 15, 2025Medical Communications, Research and Development Pharvaris, Rare Diseases, US Food and Drug Administration, clinical trial, genetic condition, new drug application
Pharvaris has announced that its data from its phase 3 study of deucrictibant immediate-release capsules (IR) for the treatment of …
